Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
Conditions
Interventions
Intervention1: KabaSuraKudineerChooranam: Decoction â?? Two times daily before 30 min of meals for 7 days
Intervention2: AmukkaraChooranamMathirai: 2 tablet - Three times daily after meals for 7 days
Sponsors
District Administration
Eligibility
Inclusion criteria
Inclusion criteria: Adult Male/Female subjects above the age of 18 years COVID -19 Positive as determined by RT-PCR Willing to provide written/digital informed consent. COVID - 19 Positive with no clinical signs COVID - 19 Positive with mild symptoms â?? Sneezing, Cough, Sore Throat, Throat Pain, Malaise, Tiredness, Fever, loss of smell, loss of taste COVID - 19 Positive with moderate symptoms â?? Fever with cough, breathlessness but respiratory rate 95% at rest
Exclusion criteria
Exclusion criteria: Pregnant and Lactating females COVID - 19 Positive with Severe symptoms â?? Respiratory distress ( >24 breath per minute), Oxygen saturation Chronic Renal Failure requiring dialysis (eGFR Known cases of uncontrolled Diabetes ( >9% HbA1c) Known cases of stage 3 Hypertension ( > 160/100 mmHg) Subjects having any medical or surgical condition that would require immediate medical or surgical intervention at the time of screening Subjects having immune compromised status like HIV, Hepatitis, Tuberculosis, Cancer etc. Subjects taking Steroid treatment and or any kind of immunosuppressive therapy Subjects who are participating in any other clinical study or having participated in any other study 1 month prior to screening in the present study. Subjects with bleeding disorders and severe anemia (Hb
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Reduction in Viral load of SARS-CoVid 2 at the end of treatment Reduction in clinical symptoms like fever, cough and breathlessness Fever: â?¤36.6°C or axilla, â?¤37.2 °C oral or â?¤37.8°C rectal or tympanic Respiratory rate - â?¤24/minute on room air Cough - mild or absent on a patient reported scale (cough symptoms score â?¤ 2 points) Timepoint: 7 days | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in incidence of complications Reduction in hospital time Laboratory markers (Laboratory Markers In Covid-19 Patients ) Adverse events/effects Timepoint: 7 days | — |
Countries
India
Contacts
Public ContactDrPSathya Rajeshwaran
Government PHC
Outcome results
None listed